Search Results
Your search for The ASCO ,The ASCO matches 20581 pages
Showing 5051 - 5100Atezolizumab/Carboplatin as Immune Induction in Patients With Metastatic Invasive Lobular Breast Cancer
First results from the phase II GELATO study evaluating atezolizumab plus carboplatin presented at the ESMO Breast Cancer Virtual Congress 2021 demonstrated clinical benefit in patients with metastatic invasive lobular breast cancer, particularly in patients with triple-negative invasive lobular...
Biomarker Analysis of the KAITLIN Trial: No Subgroup Benefits More From T-DM1 Plus Chemotherapy
In the phase III KAITLIN trial, replacing adjuvant taxane and trastuzumab with ado-trastuzumab emtansine (T-DM1) did not result in a significant improvement in invasive disease-free survival in the node-positive or intent-to-treat population, as reported by Harbeck et al at the 2020 ASCO Virtual...
FDA Pipeline: Priority Reviews in Kidney and Endometrial Cancers, Cholangiocarcinoma
Recently, the U.S. Food and Drug Administration (FDA) has granted Priority Review to the combination of pembrolizumab and lenvatinib for the treatment of both advanced renal cell carcinoma (RCC) and endometrial carcinoma. The FDA also granted Priority Review to ivosidenib for the treatment of...
Evolution to HER2-Low Breast Cancer: Investigating Potential Therapeutics
The finding that breast tumors can evolve to express low HER2 potentially increases the number of patients who can benefit from new investigational agents, typically novel antibody-drug conjugate therapies, that are currently in clinical trials for HER2-low tumors. This research was presented by...
Phase II Study of Trilaciclib in Pretreated Patients With Metastatic NSCLC Initiated
PRESERVE 4 (ClinicalTrials.gov identifier: NCT04863248)—a multicenter, randomized, double-blind, placebo-controlled phase II study of trilaciclib administered prior to docetaxel in patients with metastatic non–small cell lung cancer (NSCLC) in the second- and third-line setting who have previously...
FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for Emergency Use in Adolescents
On May 10, the U.S. Food and Drug Administration (FDA) expanded the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine for the prevention of COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to include adolescents aged 12 through 15. The FDA...
How MRD Assessment May Help Guide Treatment Selection for Patients With AML
Complete morphologic remission is considered the first requirement for achieving long-term, leukemia-free survival and a potential cure in patients with acute leukemia, including acute myeloid leukemia (AML), and is the goal of all therapeutic strategies to date. Recognizing that the majority of...
ASCO and Ontario Health Publish Joint Update on Guideline for Targeted Therapy in NSCLC With Driver Alterations
ASCO and Ontario Health (Cancer Care Ontario) have jointly published an update1 to the 2017 ASCO guideline2 regarding systemic therapy recommendations for stage IV non–small cell lung cancer (NSCLC) with driver alterations. Guideline Co-Chair Nasser H. Hanna, MD, of the Indiana University Simon...
New Savings on HealthCare.gov Follow COVID Relief Package
As of April 1, additional savings may be available for new and current consumers who purchase health insurance on HealthCare.gov following passage of the American Rescue Plan. The Centers for Medicare & Medicaid Services (CMS) also extended access to the Special Enrollment Period (SEP) for the...
ASCO Answers Guide: Cancer Survivorship
As patients finish active treatment, they often wonder: “What happens next?” ASCO Answers: Cancer Survivorship assists in answering this often-difficult question by helping patients better understand survivorship, including its psychological, physical, sexual, reproductive, financial, and...
Fostering a Global Community of Early-Career Oncologists, Virtually
In a typical year, the new participants in ASCO and Conquer Cancer’s International Development and Education Awards (IDEA) and International Development and Education Awards–Palliative Care (IDEA-PC) program would arrive at the McCormick Place Convention Center just ahead of the ASCO Annual...
What You Need to Know About Cancer and the Coronavirus
As a three-time breast cancer survivor, when the COVID-19 pandemic hit the United States this past January, I knew I had to do everything I could to avoid getting the virus. A host of lingering side effects from my surgeries, chemotherapy, and radiation treatments have left me with cardiovascular...
Margetuximab-cmkb: A Novel Agent Overshadowed by an Abundance of Options in HER2-Positive Breast Cancer
It is incredible to reflect upon the scientific advances in the treatment of HER2-positive breast cancer over the past 23 years. Once considered the worst subtype of breast cancer, HER2-positive disease is now associated with the best long-term outcomes in this age of targeted treatments. With a...
UPMC Hillman Names New Hematology Oncology Chief
Taofeek K. Owonikoko, MD, PhD, will join the University of Pittsburgh Medical Center (UMPC) Hillman Cancer Center and Department of Medicine as Chief of the Division of Hematology/Oncology. A physician-scientist board-certified in medical oncology, hematology, and internal medicine, Dr. Owonikoko...
Randall F. Holcombe, MD, MBA, Named Director of UVM Cancer Center and Chief of Hematology and Oncology
The Robert Larner, MD, College of Medicine at The University of Vermont (UVM), in collaboration with the UVM Health Network and the UVM Medical Center, has announced that Randall F. Holcombe, MD, MBA, has been appointed Director of the UVM Cancer Center and Chief of the Division of Hematology and...
COVID-19 Pandemic Underscores Shortage of Oncologists
The expected surge of patients, some with advanced cancers, wanting and needing oncology care as the COVID-19 pandemic ebbs, underscores the need for more oncologists, according to Barbara L. McAneny, MD, MACP, FASCO, cofounder and Chief Executive Officer, New Mexico Oncology Hematology...
Oncologists Launch Global Society to Improve Clinical Research, Standardize Treatment, and Improve Patient Education About Rare Genitourinary Tumors
Late this past year, a group of oncologists led by Philippe E. Spiess, MD, MS, FRCS(C), FACS, Assistant Chief of Surgical Services and Senior Member in the Department of Genitourinary Oncology at Moffitt Cancer Center and Professor in the Department of Urology at the University of South Florida;...
Surge of Patients With Advanced Cancer Expected Due to Delayed Diagnosis and Treatment During Pandemic
Pent up demand for cancer screenings, diagnostic workups, and treatments delayed or curtailed since the start of the pandemic is expected to result in a surge of patients—some with more advanced disease as a result of delays—seeking appointments with oncologists. “We are starting to see the...
Lombardi Comprehensive Cancer Center, Georgetown University Names Kieron Dunleavy, MD, to Leadership Positions in Hematology
Kieron Dunleavy, MD, was appointed Director of Hematology at the Lombardi Comprehensive Cancer Center, Georgetown University, in Washington, DC. He is now also Chief of the Lymphoma Program at Georgetown University. Dr. Dunleavy joined Lombardi/Georgetown earlier this year. He is former Professor...
FDA Approves Nivolumab in Combination With Chemotherapy for Metastatic Gastric Cancer and Esophageal Adenocarcinoma
On April 16, 2021, the U.S. Food and Drug Administration (FDA) approved nivolumab (Opdivo) in combination with fluoropyrimidine- and platinum-containing chemotherapy for advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma. CheckMate 649 The...
Roswell Park Is First Site in Region Named a Resource for Patients With Rare Genetic Disease
Living with a genetic disorder that calls for regular monitoring, appropriate treatment, and emotional support calls for a multidisciplinary team that works together to coordinate patient care. Those diagnosed with von Hippel-Lindau (VHL) disease have a resource for complete and coordinated care in ...
AACR Inaugurates New Leadership at Virtual AACR Annual Business Meeting 2021
The American Association for Cancer Research (AACR) welcomed David A. Tuveson, MD, PhD, FAACR, as President of the organization for 2021–2022. He was inaugurated during the AACR Annual Business Meeting, held virtually on April 12. Dr. Tuveson is Director of the Cold Spring Harbor Laboratory Cancer...
Cannabis
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this article, Nirupa Raghunathan, MD, and Jyothirmai Gubili, MS, focus on the increasing use...
City of Hope Renames Research Center as the Arthur Riggs Diabetes & Metabolism Research Institute
City of Hope has announced the renaming of its diabetes research center as the Arthur Riggs Diabetes & Metabolism Research Institute, in honor of its long-time director and research pioneer. Arthur Riggs, PhD, is known for scientific achievements that include developing the technology leading...
Dana-Farber Cancer Institute Opens New State-of-the-Art Location
Dana-Farber Cancer Instituterecently announced a major expansion with the opening of a hospital facility in Chestnut Hill, Massachusetts, to provide increased cancer care and outpatient services for adult patients in the region. The new 140,000–square foot, state-of-art outpatient facility is...
A Sense of Duty Shapes the Career of Medical Oncologist Aparna Parikh, MD
By way of her family lineage, Aparna Parikh, MD, seemed destined for a career in medicine. “Both of my parents are physicians, as well as my maternal grandfather. I have two other siblings, all of whom are in the medical field. Medicine has always been part of my life since childhood. My parents...
‘MethylationToActivity’: A Deep Learning Framework for Epigenetic Research
Scientists at St. Jude Children’s Research Hospital are using a type of machine learning to put a new twist on an established technique. The researchers created MethylationToActivity (M2A), a framework for using DNA methylation data to reveal promoter activity and gene expression. The results were...
Bispecific Antibody Platform: Early Data in Relapsed and Refractory Myeloma
“There was never a night or a problem that could defeat sunrise or hope.” —Bernard Williams To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting...
UCLA Team Receives $6 Million From NIH to Explore New Pancreatic Cancer Therapies
A team of researchers from the University of California at Los Angeles (UCLA) Jonsson Comprehensive Cancer Center has been awarded two research grants totaling $6 million from the National Institutes of Health (NIH) to identify new ways to treat pancreatic cancer. “Pancreatic cancer is one of the ...
New Director of Neuro-Oncology Named to Rutgers Cancer Institute of New Jersey
Rutgers Cancer Institute of New Jersey has appointed Michael E. Salacz, MD, as Director of its Neuro-Oncology Program. The Associate Professor of Medicine at Rutgers Robert Wood Johnson Medical School joins Rutgers Cancer Institute from the University of Kansas Medical Center, where he served as...
Frederick W. Alt, PhD, Honored With 2021 AACR Award for Lifetime Achievement in Cancer Research
The American Association for Cancer Research (AACR) is recognizing geneticist Frederick W. Alt, PhD, with the 18th AACR Award for Lifetime Achievement in Cancer Research. Dr. Alt is a Howard Hughes Medical Institute investigator, Director of the Program in Cellular and Molecular Medicine at Boston ...
Expert Point of View: Ursula Matulonis, MD, and Konstantin Zakashansky, MD
Perspectives on ARIEL4 were provided for The ASCO Post by the invited discussant Ursula Matulonis, MD, Professor of Medicine, Harvard Medical School, and Chief of Gynecologic Oncology and the Brock Wilson Family Chair at Dana-Farber Cancer Institute, Boston, and by Konstantin Zakashansky, MD,...
Maryam Lustberg, MD, MPH, Accepts Leadership Roles at Smilow Cancer Hospital, Yale Cancer Center
Maryam Lustberg, MD, MPH, has been appointed Director of The Breast Center at Smilow Cancer Hospital and Chief of Breast Medical Oncology at Yale Cancer Center. She will also join the faculty at Yale Cancer Center as Associate Professor of Medicine (Medical Oncology). Dr. Lustberg joins Yale from...
Squamous Cell Carcinoma of the Head and Neck: Current Status and Future Directions
Although head and neck cancers include multiple histologies and primary sites, squamous cell carcinomas (SCC) originating in the oropharynx, oral cavity, larynx, or hypopharynx are the most common. Today, we recognize several different types of head and neck diseases, primarily those that are human ...
Shared Risk Factors for Preventing Cancer and Cardiovascular Disease: The Evolving Focus of Cardio-oncology
Cardio-oncology represents the intersection of cancer and cardiovascular disease. Cancer therapies can result in cardiovascular complications, and some patients become less attentive to their chronic disease management after a diagnosis of cancer. As cancer patients are living longer, for some,...
Virtual Meetings Are Here to Stay
In 2020, the 8th Annual Beirut Breast Cancer Conference (BBCC) was our last in-person meeting. The first cases of COVID-19 started in Lebanon around the end of February 2020, and the pandemic continues into its second year, with waves of rising cases following superspreader events and other likely...
Chênevert Family Brain Tumor Center Launched at Yale
Yale School of Medicine recently announced a gift to establish the Chênevert Family Brain Tumor Center at Yale Cancer Center. The Center will be a leading institution in worldwide neuro-oncology research, bringing groundbreaking solutions and hope to patients with brain tumors. The gift will...
John Marshall, MD, and Liza Marshall: When Cancer Strikes an Oncologist’s Family
John Marshall, MD, of the Lombardi Cancer Center at Georgetown University, and his wife, Liza Marshall, a breast cancer survivor, talk about the impact of her diagnosis, how it changed their view of cancer care and the way clinicians communicate, and why their memoir has an important message.
Dr. John and Liza Marshall on Their New Book Off Our Chests: A Candid Tour Through the World of Cancer
This week, The ASCO Post sat down with Dr. John Marshall, of the Lombardi Cancer Center at Georgetown University, and his wife, Liza Marshall, a former lawyer, active advocate for patients with cancer, and a breast cancer survivor. The Marshalls are the coauthors of a new book entitled Off Our...
Study Explores Racial Disparities in Renal Cell Carcinoma by Stage and Mortality
Research recently published by Valencia et al in the journal Cancers found that advanced-stage kidney cancer is more common in Hispanic American and Native American patients than in non-Hispanic White patients. Using data from the National Cancer Database and the Arizona Cancer Registry,...
Increased Loneliness Among Patients With Cancer During the COVID-19 Pandemic May Affect Symptom Burden
Loneliness and social isolation have been significant problems for the general population during the COVID-19 pandemic, but for patients with cancer, these issues were particularly acute, likely due to isolation and social distancing, according to a recent study published by Miaskowski et al in the ...
Prospective Study Explores Prostate Cancer and Treatment Outcomes By Race
A study designed to enroll an equal number of Black and White men with advanced prostate cancer confirmed key findings that have been evident in retrospective analyses and suggest potential new avenues for treating Black patients who disproportionately die of the disease. Researchers at Duke Cancer ...
AI System May Aid in Diagnosing Cancer of Unknown Primary
In 1% to 2% of cancer cases, the primary site of tumor origin cannot be determined. Because many modern cancer therapeutics target primary tumors, the prognosis for a cancer of unknown primary (CUP) is poor, with a median overall survival of 2.7 to 16 months. In order to receive a more specific...
Karen E. Knudsen, MBA, PhD: The American Cancer Society’s First Female CEO Speaks Out
Karen E. Knudsen, MBA, PhD, of Sidney Kimmel Cancer Center at Jefferson Health, was recently appointed Chief Executive Officer of the American Cancer Society—the first female to head the organization in its 107-year history. Dr. Knudsen talks about the opportunities she sees ahead for the Society...
FDA Grants Accelerated Approval to Pembrolizumab Combination for HER2-Positive Gastric Cancer
On May 5, the U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab (Keytruda) in combination with trastuzumab plus fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic...
Accuracy of Lung Cancer Risk Model in Diverse Populations
A commonly used risk prediction model does not accurately identify high-risk Black patients with lung cancer who could gain life-saving benefit from early screening—paving the way for improving screenings and guidelines. These findings were published in a research letter by Shusted et al in JAMA...
Expert Panel–Endorsed Quality Measures for End-of-Life Care for Children With Cancer
There is currently no consensus on what quality end-of-life care for children with cancer looks like, or how to measure and deliver it; however, investigators recently assembled an expert panel to help fill this void. In a study published by Emily Johnston, MD, MS, and colleagues in the journal...
Imaging Study Aims to Detect Rates of Cancer in Medieval Britain
The first study to use x-rays and computed tomography (CT) to detect evidence of cancer among the skeletal remains of a preindustrial population suggests that between 9% to 14% of adults in medieval Britain had the disease at the time of their death. These findings were published by Mitchell et al...
Risk of Colorectal Cancer and Colorectal Polyps in First-Degree Family Members
Researchers have demonstrated a possible connection between colorectal polyps in close relatives and the risk of developing colorectal cancer. The study, which was published by Song et al in the British Medical Journal, is of potential consequence for cancer screening procedures. Colorectal cancer...
FDA Pipeline: Priority Reviews of Treatments for Bladder and Lung Cancers
Recently, the U.S. Food and Drug Administration (FDA) granted Priority Review designation to treatments for surgically resected, high-risk, muscle-invasive urothelial carcinoma and epidermal growth factor receptor exon 20 insertion mutation–positive metastatic non–small cell lung cancer (NSCLC)....
